Cresemba is an azole antifungal with a Qualified Infectious Disease Product (QIDP) designation. Its priority review and subsequent approval was based on a clinical trial involving 516 patients randomized to either Cresemba or voriconazole for the treatment of invasive aspergillosis, as well as a single-arm clinical trial involving 37 patients treated with Cresemba for mucormycosis. Results from both studies showed that Cresemba was safe and effective in treating the fungal infections.
Cresemba has been approved as both oral and intravenous (IV) formulations.
For more information call (877) 828-7942 or visit Astellas.com.